Form 4: Phreesia SVP David Linetsky Sells Shares Under 10b5-1 Trading Plan

David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 720 shares of common stock at an average price of $29.5013 per share on February 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 5, 2025, David Linetsky, the SVP of Life Sciences at Phreesia, Inc., sold 720 shares of the company's common stock.
• The sale was executed at a weighted average price of $29.5013 per share.
• The prices for individual transactions ranged from $29.50 to $29.52.
• This transaction was conducted under a Rule 10b5-1 trading plan adopted on July 18, 2024.
• Following the transaction, Linetsky directly owns 230,051 shares and indirectly owns 8,851 shares through his spouse.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of an insider stock sale under a pre-arranged trading plan.

Industry Context

This is a routine disclosure of an insider stock sale. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Phreesia, David Linetsky, stock sale, Form 4, Rule 10b5-1, insider trading, securities